Results 71 to 80 of about 30,112 (235)

Impact of Body Weight Loss During Preoperative Chemoradiotherapy on Prognosis of Patients With Lower Rectal Cancer

Annals of Gastroenterological Surgery, EarlyView.
The present study aimed to investigate the relationship between changes in body weight and composition during chemoradiotherapy, such as the psoas muscle mass index, visceral fat index, and subcutaneous fat index obtained from computed tomography images, and long‐term outcomes in rectal cancer patients.
Shinya Abe, Hiroaki Nozawa, Kazuhito Sasaki, Koji Murono, Shigenobu Emoto, Yuichiro Yokoyama, Yuzo Nagai, Yuzo Harada, Takahide Shinagawa, Soichiro Ishihara   +9 more
wiley   +1 more source

Recurrent mucinous carcinoma with sarcomatoid and sarcomatous mural nodules: a case report and literature review

Frontiers in Oncology
Ovarian mucinous tumors with sarcomatous mural nodules are rare. Sarcomatous nodules have a bad prognosis. Its diagnosis and treatment are controversial.It is still controversial whether malignant mural nodules represent a dedifferentiated form of ...
Simin Li, Jingyu Zhu, Na Jiang, Yanping Guo, Meng Hou, Xi Liu, Jin Yang, Xiaofeng Yang   +7 more
doaj   +1 more source

Endocrine cell micronests in an ovarian mucinous borderline tumor: a potential diagnostic pitfall for microinvasion

Diagnostic Pathology, 2022
The occurrence of endocrine cell micronests in ovarian tumors is rarely reported. To our knowledge, there are only three prior cases reported to date: one occurring in an ovarian mucinous cystadenoma, one in an ovarian mucinous cystadenofibroma, and ...
Katrina Collins, Sheila Segura, Michael Hwang   +2 more
doaj   +1 more source

Therapeutic Applications of Stimuli‐Based Release and Engineering of Extracellular Vesicles

Advanced NanoBiomed Research, EarlyView.
This review summarizes the effects of endogenous and exogenous stimuli, their effects on the natural release of extracellular vesicles, as well as their uptake and release. It also gives an overview of stimuli‐responsive EVs and their therapeutic applications. Extracellular vesicles (EVs), nano‐ to microsized lipid bilayer membrane‐bound particles, are
Gloria Kemunto, Kristen Dellinger
wiley   +1 more source

Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study

BMC Cancer, 2008
Background Mucinous ovarian carcinoma have a poorer prognosis compared with other histological subtypes. The aim of this study was to evaluate, retrospectively, the activity of chemotherapy in patients with platinum sensitive recurrent mucinous ovarian ...
Alletti Desiderio, Breda Enrico, Lauria Rossella, Manzione Luigi, Ghezzi Fabio, Mereu Liliana, Villa Antonella, Katsaros Dionyssios, Cormio Gennaro, Odicino Franco, Scollo Paolo, Scarfone Giovanna, Ferrandina Gabriella, Pignata Sandro, Ballardini Michela, Lombardi Alessandra, Sorio Roberto, Mangili Giorgia, Priolo Domenico, Magni Giovanna, Morabito Alessandro   +20 more
doaj   +1 more source

What Is New on Ovarian Carcinoma: Integrated Morphologic and Molecular Analysis Following the New 2020 World Health Organization Classification of Female Genital Tumors

Diagnostics, 2021
Ovarian carcinomas represent a heterogeneous group of neoplasms consisting of separate entities with distinct risk factors, precursor lesions, pathogenesis, patterns of spread, molecular profiles, clinical course, response to chemotherapy, and outcomes ...
Antonio De Leo, Donatella Santini, Claudio Ceccarelli, Giacomo Santandrea, Andrea Palicelli, Giorgia Acquaviva, Federico Chiarucci, Francesca Rosini, Gloria Ravegnini, Annalisa Pession, Daniela Turchetti, Claudio Zamagni, Anna Myriam Perrone, Pierandrea De Iaco, Giovanni Tallini, Dario de Biase   +15 more
doaj   +1 more source

Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms [PDF]

, 2015
Background: Mucinous ovarian tumors represent a distinct histotype of epithelial ovarian cancer. The rarest (2-4 % of ovarian carcinomas) of the five major histotypes, their genomic landscape remains poorly described.
Anglesio, Michael S., Bakkum-Gamez, Jamie, Garcia, Joaquin J., Gilks, Blake C., Halling, Kevin, Huntsman, David G., Karnezis, Anthony, Kipp, Benjamin R., Kommoss, Stefan, Mackenzie, Robertson, McAlpine, Jessica N., Prigge, Elena-Sophie, Reuschenbach, Miriam, Senz, Janine, von Knebel-Doeberitz, Magnus, Voss, Jesse, Winterhoff, Boris J., Yang, Winnie   +17 more
core   +1 more source

Tumor Infiltrating Lymphocyte Therapy Combined With PD‐1/LAG‐3 Inhibition in Patients With Recurrent Platinum‐Resistant Ovarian Cancer

International Journal of Cancer, EarlyView.
The detection of tumor‐infiltrating lymphocytes (TILs) is a positive prognostic factor in ovarian cancer. Moreover, TILs are significantly boosted by immunotherapy, though ovarian cancer patients have seen limited benefit from immune therapies. This study investigated the safety and feasibility of TIL therapy combined with PD‐1 and LAG‐3 inhibitors in ...
Tine J. Monberg, Cathrine L. Lorentzen, Marie C. W. Westergaard, Trine Z. Iversen, Troels H. Borch, Marco Donia, Sigrid M. Mannering, Stine E. W. Banke, Özcan Met, Inge Marie Svane   +9 more
wiley   +1 more source

Cellular origins of mucinous ovarian carcinoma

The Journal of Pathology
AbstractMucinous ovarian carcinoma (MOC) is a rare histotype of epithelial ovarian cancer. Its origins are obscure: while many mucinous tumours in the ovary are metastases from the gastrointestinal tract, MOC can occur as an ovarian primary; however, the cell of origin is not well established.
Nicola S Meagher, Martin Köbel, Anthony N Karnezis, Aline Talhouk, Michael S Anglesio, Andrew Berchuck, Simon A Gayther, Paul PD Pharoah, Penelope M Webb, Susan J Ramus, Kylie L Gorringe   +10 more
openaire   +2 more sources

Clinical trial of safety and antitumor activity of farletuzumab ecteribulin in patients with platinum‐resistant ovarian cancer: Phase I expansion results

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract Objective In the dose‐escalation part of Study 101, which included multiple tumor types, objective responses were observed in 10 of 22 patients across multiple dose levels of farletuzumab ecteribulin (FZEC). We explored the safety/antitumor activity of FZEC in patients with platinum‐resistant ovarian cancer (PROC) from the Study 101 expansion ...
Kan Yonemori, Mayu Yunokawa, Koji Matsumoto, Kazuhiro Takehara, Kosei Hasegawa, Yasuyuki Hirashima, Hidenori Kato, Hiroki Ikezawa, Yohei Otake, Wataru Yusa, Takuma Miura, Shin Nishio   +11 more
wiley   +1 more source